The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

The global liraglutide and semaglutide market accounted for USD 15.87 billion in 2023 and is expected to reach USD 51.83 billion by 2034 with a CAGR of 11.36% during the forecast period 2024-2034.

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 medication injected daily instead of weekly.

No medications are currently approved for the treatment of nonmonogenic, nonsyndromic obesity in children younger than 12 years of age. Although the use of liraglutide has been shown to induce weig ...

Liraglutide is the first GLP-1 agonist to show benefit in this age group and could provide young patients a much-needed option.

New study reveals semaglutide outperforms liraglutide in weight loss for obesity, highlighting key factors that contribute to significant weight reduction in patients. Study: One-Year Weight ...

For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days, ...

Liraglutide is an older version of the popular GLP-1 drugs, which include Ozempic. But questions remain about starting kids on a lifelong drug so young.

Patents for a drug related to Ozempic have expired, so pharmaceutical companies are working to develop ‘generic’ versions. These are likely to be much cheaper. But how do they compare with ...

Researchers assess the role of liraglutide in regulating iron metabolism in a mouse model of hereditary hemochromatosis.

The FDA is currently considering approval of liraglutide for the treatment of severe obesity in children ages 6-12. The review comes on the heels of a randomized trial published in the New England ...